Royalty Pharma Q3 Portfolio Receipts up 11%, guidance raised

Reuters11-05

Royalty Pharma Q3 Portfolio Receipts up 11%, guidance raised

Overview

Royalty Pharma Q3 2025 Portfolio Receipts grow 11% yr/yr to $814 mln
Adjusted EBITDA for Q3 2025 beats analyst expectations
Company raises full-year 2025 guidance for Portfolio Receipts to $3.2-$3.25 bln

Outlook

Royalty Pharma raises 2025 Portfolio Receipts guidance to $3,200 mln-$3,250 mln
Company expects 2025 Portfolio Receipts growth of 14% to 16%
Royalty Pharma sees negligible FX impact on 2025 Portfolio Receipts

Result Drivers

ROYALTY RECEIPTS GROWTH - Driven by strong performance of Voranigo, Tremfya, and cystic fibrosis franchise
CAPITAL DEPLOYMENT - Expanded portfolio with acquisitions including Imdelltra and Amvuttra

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Adjusted EBITDA	Beat	$779 mln	$695.81 mln (4 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Royalty Pharma PLC is $42.50, about 11% above its November 4 closing price of $37.84
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nGNX8cFqQg

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581724947?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581724947","market":"us","top_or_hot":-1,"title":"Royalty Pharma Q3 Portfolio Receipts up 11%, guidance raised","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Royalty Pharma Q3 Portfolio Receipts up 11%, guidance raised</title></head><body><p><span>Overview</span></p><ul><li><p>Royalty Pharma Q3 2025 Portfolio Receipts grow 11% yr/yr to $814 mln</p></li><li><p>Adjusted EBITDA for Q3 2025 beats analyst expectations</p></li><li><p>Company raises full-year 2025 guidance for Portfolio Receipts to $3.2-$3.25 bln</p></li></ul><p><span>Outlook</span></p><ul><li><p>Royalty Pharma raises 2025 Portfolio Receipts guidance to $3,200 mln-$3,250 mln</p></li><li><p>Company expects 2025 Portfolio Receipts growth of 14% to 16%</p></li><li><p>Royalty Pharma sees negligible FX impact on 2025 Portfolio Receipts</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ROYALTY RECEIPTS GROWTH - Driven by strong performance of Voranigo, Tremfya, and cystic fibrosis franchise</p></li><li><p>CAPITAL DEPLOYMENT - Expanded portfolio with acquisitions including Imdelltra and Amvuttra</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Adjusted EBITDA</p></td><td><p>Beat</p></td><td><p>$779 mln</p></td><td><p>$695.81 mln (4 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Royalty Pharma <a href=\"https://laohu8.com/S/PLC\">PLC</a> is $42.50, about 11% above its November 4 closing price of $37.84</p></li><li><p>The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago</p></li></ul><p>Press Release: <span>ID:nGNX8cFqQg</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Royalty Pharma Q3 Portfolio Receipts up 11%, guidance raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoyalty Pharma Q3 Portfolio Receipts up 11%, guidance raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 20:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Royalty Pharma Q3 Portfolio Receipts up 11%, guidance raised</title></head><body><p><span>Overview</span></p><ul><li><p>Royalty Pharma Q3 2025 Portfolio Receipts grow 11% yr/yr to $814 mln</p></li><li><p>Adjusted EBITDA for Q3 2025 beats analyst expectations</p></li><li><p>Company raises full-year 2025 guidance for Portfolio Receipts to $3.2-$3.25 bln</p></li></ul><p><span>Outlook</span></p><ul><li><p>Royalty Pharma raises 2025 Portfolio Receipts guidance to $3,200 mln-$3,250 mln</p></li><li><p>Company expects 2025 Portfolio Receipts growth of 14% to 16%</p></li><li><p>Royalty Pharma sees negligible FX impact on 2025 Portfolio Receipts</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ROYALTY RECEIPTS GROWTH - Driven by strong performance of Voranigo, Tremfya, and cystic fibrosis franchise</p></li><li><p>CAPITAL DEPLOYMENT - Expanded portfolio with acquisitions including Imdelltra and Amvuttra</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Adjusted EBITDA</p></td><td><p>Beat</p></td><td><p>$779 mln</p></td><td><p>$695.81 mln (4 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Royalty Pharma <a href=\"https://laohu8.com/S/PLC\">PLC</a> is $42.50, about 11% above its November 4 closing price of $37.84</p></li><li><p>The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago</p></li></ul><p>Press Release: <span>ID:nGNX8cFqQg</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH0LI:1","article_id":"2581724947","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581724947","pubTimestamp":1762345264,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Royalty Pharma Q3 Portfolio Receipts up 11%, guidance raisedOverviewRoyalty Pharma Q3 2025 Portfolio Receipts grow 11% yr/yr to $814 mlnAdjusted EBITDA for Q3 2025 beats analyst expectationsCompany ra","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RPRX":"Royalty Pharma plc"},"translate_title":"Royalty Pharma第三季度投资组合收入增长11%，指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RPRX":0.9},"content_text":"Royalty Pharma Q3 Portfolio Receipts up 11%, guidance raisedOverviewRoyalty Pharma Q3 2025 Portfolio Receipts grow 11% yr/yr to $814 mlnAdjusted EBITDA for Q3 2025 beats analyst expectationsCompany raises full-year 2025 guidance for Portfolio Receipts to $3.2-$3.25 blnOutlookRoyalty Pharma raises 2025 Portfolio Receipts guidance to $3,200 mln-$3,250 mlnCompany expects 2025 Portfolio Receipts growth of 14% to 16%Royalty Pharma sees negligible FX impact on 2025 Portfolio ReceiptsResult DriversROYALTY RECEIPTS GROWTH - Driven by strong performance of Voranigo, Tremfya, and cystic fibrosis franchiseCAPITAL DEPLOYMENT - Expanded portfolio with acquisitions including Imdelltra and AmvuttraKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Adjusted EBITDABeat$779 mln$695.81 mln (4 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for Royalty Pharma PLC is $42.50, about 11% above its November 4 closing price of $37.84The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months agoPress Release: ID:nGNX8cFqQgFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581724947","isCrawlerRequest":true}